Please register to access the learning network
This online learning network provides members with information and support around general practice working at scale.
Members have access to useful resources and case studies as well as opportunities to share learning from their experiences and make useful links with other at scale organisations.
Whether you have been working at scale for a while or just want to find out more, this network can support you in your journey and connect you to colleagues across the country who are working in innovative ways.
Membership is open to people working in GP practices and other organisations that support them. Register now to become a member of the learning network.
RCGP RSS News FeedCollege welcomes national action plan in the fight against antibiotic resistance
She said: "Antibiotic resistance is one of the biggest and most dangerous threats to modern healthcare, and the more high-level support we get to tackle this problem, the better.
"GPs are already making excellent headway in reducing antibiotic use in the community and will only prescribe when they are absolutely necessary and the best course of action for the patient sitting in front of us.
"However, as this national action plan highlights, this is a society-wide issue and not something GPs can be held responsible for tackling on their own.
"We need to get to a stage where antibiotics are not seen by patients as a 'catch all' for every illness, but rather as a serious drug option, usually reserved for when all other treatment options have either failed or been deemed inappropriate.
"Sore throats, for example, are usually caused by viral infections that antibiotics will not help, but they are also usually self-limiting and will get better on their own in a few days with the help of basic over-the-counter pain relief, such as paracetamol and ibuprofen.
"It's crucial that we continue to get this message out, so that we can carry on delivering safe, effective care to our patients both now and in the future.
"It's also astonishing that there hasn't been a new and approved class of antibiotics produced in over 30 years – there have recently been some promising signs, but it’s clear that more investment in the research and development of new drugs to tackle emerging diseases is desperately needed, and if offering appropriate incentives and NHS collaborations with pharmaceutical companies are demonstrated to safely support this, then they should be encouraged."